Sigyn Therapeutics (SIGY) Operating Leases (2021 - 2025)
Sigyn Therapeutics (SIGY) posted Operating Leases of $109800.0 for Q1 2025, up 94.83% sequentially from $56356.0 in Q4 2024, and down 36.55% YoY from $173038.0 in Q1 2024.
Sigyn Therapeutics (SIGY) Operating Leases (2021 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Operating Leases for 5 years, with the latest figure at $109800.0 in Q1 2025.
- Quarterly Operating Leases fell 36.55% year-over-year to $109800.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $109800.0 (down 36.55% YoY) and the FY2024 annual result came in at $56356.0, down 55.38% from the prior year.
- Operating Leases grew to $109800.0 in Q1 2025 per SIGY's latest filing, from $56356.0 in the prior quarter.
- Over five years, Operating Leases peaked at $261782.0 in Q2 2021 and troughed at $56356.0 in Q4 2024.
- A 5-year average of $175500.2 and a median of $194441.0 in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases climbed 0.0% in 2023, then slumped 62.9% in 2024.
- Over 5 years, Operating Leases stood at $240625.0 in 2021, then declined by 22.11% to $187425.0 in 2022, then slumped by 32.61% to $126302.0 in 2023, then tumbled by 55.38% to $56356.0 in 2024, then soared by 94.83% to $109800.0 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $109800.0, $56356.0, and $74748.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 109,800.00 |
| Dec 31, 2024 | 56,356.00 |
| Sep 30, 2024 | 74,748.00 |
| Jun 30, 2024 | 92,689.00 |
| Mar 31, 2024 | 173,038.00 |
| Dec 31, 2023 | 126,302.00 |
| Sep 30, 2023 | 201,459.00 |
| Jun 30, 2023 | 158,098.00 |
| Mar 31, 2023 | 228,136.00 |
| Dec 31, 2022 | 187,425.00 |
| Sep 30, 2022 | 201,457.00 |
| Jun 30, 2022 | 215,146.00 |
| Mar 31, 2022 | 228,135.00 |
| Dec 31, 2021 | 240,625.00 |
| Sep 30, 2021 | 252,807.00 |
| Jun 30, 2021 | 261,782.00 |